doi:10.1016/j.regpep.2006.02.007 5
The documented 64.8% one-year discontinuation rate among non-diabetic GLP-1 RA users in the United States is consistent with multiple contributing factors
Moreover, based on the reduction in major cardiovascular events observed with use of GLP-1R agonists in cardiovascular outcome trials in people with type 2 diabetes [89], large-scale outcome trials in overweight and obesity have been initiated (ClinicalTrials.gov registration no
Role of carnitine The common mild elevation in aminotransferases is usually reversible when VPA therapy is discontinued or the dose reduced
This method offers consistent bioavailability and precise dosing, improving research accuracy
Ek A, Brissman M, Nordin K, Eli K, Nowicka P